Ignite Creation Date:
2024-05-05 @ 5:00 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00362102
Status:
COMPLETED
Last Update Posted:
2016-11-22
First Post:
2006-08-08
Brief Title:
A Phase II Study of Cetuximab Plus Irinotecan in Patients With EGFR-detectable Metastatic Colorectal Carcinoma
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Colorectal Carcinoma |
Keywords:
| Name | View |
|---|---|
| EGFR-detectable metastatic colorectal carcinoma with documented progressive disease to irinotecan-based chemotherapy and failure | View |